lots of changes

_bibliography/papers.bib

@@ -1,6 +1,89 @@
 % Generated by Paperpile. Check out https://paperpile.com for more information.
 % BibTeX export options can be customized via Settings -> BibTeX.
 
+@ARTICLE{Mian2024-ch,
+  title     = "Development of non-sedating benzodiazepines with in vivo
+               antischistosomal activity",
+  author    = "Mian, Md Yeunus and Sharmin, Dishary and Mondal, Prithu and
+               Belayet, Jawad Bin and Hossain, M Mahmun and McCusker, Paul and
+               Ryan, Kaetlyn T and Fedorov, Alexander Y and Green, Heather A and
+               Ericksen, Spencer S and Zamanian, Mostafa and Tiruveedhula, V V N
+               Phani Babu and Cook, James M and Chan, John D",
+  journal   = "Antimicrob. Agents Chemother.",
+  publisher = "American Society for Microbiology",
+  volume    =  68,
+  number    =  9,
+  pages     = "e0036924",
+  abstract  = "The neglected tropical disease schistosomiasis infects over 200
+               million people worldwide and is treated with just one
+               broad-spectrum antiparasitic drug (praziquantel). Alternative
+               drugs are needed in the event of emerging praziquantel resistance
+               or treatment failure. One promising lead that has shown efficacy
+               in animal models and a human clinical trial is the benzodiazepine
+               meclonazepam, discovered by Roche in the 1970s. Meclonazepam was
+               not brought to market because of dose-limiting sedative side
+               effects. However, the human target of meclonazepam that causes
+               sedation (GABAARs) is not orthologous to the parasite targets
+               that cause worm death. Therefore, we were interested in whether
+               the structure of meclonazepam could be modified to produce
+               antiparasitic benzodiazepines that do not cause host sedation. We
+               synthesized 18 meclonazepam derivatives with modifications at
+               different positions on the benzodiazepine ring system and tested
+               them for in vitro antiparasitic activity. This identified five
+               compounds that progressed to in vivo screening in a murine model,
+               two of which cured parasite infections with comparable potency to
+               meclonazepam. When these two compounds were administered to mice
+               that were run on the rotarod test, both were less sedating than
+               meclonazepam. These findings demonstrate the proof of concept
+               that meclonazepam analogs can be designed with an improved
+               therapeutic index and point to the C3 position of the
+               benzodiazepine ring system as a logical site for further
+               structure-activity exploration to further optimize this chemical
+               series.",
+  month     =  sep,
+  year      =  2024,
+  keywords  = "anthelmintic; benzodiazepine; schistosomiasis",
+  doi       = "10.1128/aac.00369-24",
+  pmc       = "PMC11373208",
+  pmid      =  39136467,
+  issn      = "1098-6596,0066-4804",
+  language  = "en",
+  pdf      = {Mian et al. 2024 - Development of non-sedating benzodiazepines with in vivo antischistosomal activity.pdf},
+  preview  = {Mian et al. 2024 - Development of non-sedating benzodiazepines with in vivo antischistosomal activity.jpeg}
+}
+
+@ARTICLE{Collins2024-fs,
+  title     = "Lack of correlation between parasite burden and key weight
+               metrics in poultry infected with intestinal ascarids",
+  author    = "Collins, J B and Shaver, Amanda O and Schaye, Etta S and Volpe,
+               Tom and Nunn, Leonardo R and Zamanian, Mostafa and Andersen, Erik
+               C",
+  journal   = "MicroPubl. Biol.",
+  publisher = "California Institute of Technology",
+  volume    =  2024,
+  abstract  = "Ascaridia galli and Ascaridia dissimilis are the most common and
+               economically impactful nematode parasites of commercial poultry.
+               These infections rarely cause clinical disease, but reduction in
+               feed conversion efficiency is detected. To determine if feed
+               conversion efficiency reductions correlate with any physiological
+               measures independent of clinical disease, we determined if
+               ascarid infections correlate with changes in the weights of the
+               small intestine, liver, or total animal weight (quantitative
+               measures of animal health). No correlation between parasite
+               burden and these metrics were observed, supporting the concept
+               that feed conversion is the only production metric impacted by
+               ascarid infections.",
+  month     =  aug,
+  year      =  2024,
+  doi       = "10.17912/micropub.biology.001197",
+  pmc       = "PMC11339651",
+  pmid      =  39176285,
+  issn      = "2578-9430",
+  language  = "en",
+  pdf      = {Collins et al. 2024 - Lack of correlation between parasite burden and key weight metrics in poultry infected with intestinal ascarids.pdf},
+  preview  = {Collins et al. 2024 - Lack of correlation between parasite burden and key weight metrics in poultry infected with intestinal ascarids.jpeg}
+}
+
 @ARTICLE{Ciuoderis2024-qy,
   title    = "Detection of Mansonella ozzardi in patients with acute febrile
               illness in Colombia",
@@ -36,52 +119,6 @@ @ARTICLE{Ciuoderis2024-qy
   preview  = {Ciuoderis et al. 2024 - Detection of Mansonella ozzardi in patients with acute febrile illness in Colombia.jpeg}
 }
 
-
-@ARTICLE{Mian2024-gs,
-  title    = "Development of non-sedating antischistosomal benzodiazepines",
-  author   = "Mian, Md Yeunus and Sharmin, Dishary and Mondal, Prithu and
-              Belayet, Jawad Bin and Mahmun Hossain, M and McCusker, Paul and
-              Ryan, Kaetlyn T and Fedorov, Alexander Y and Green, Heather A and
-              Ericksen, Spencer S and Zamanian, Mostafa and Phani Babu
-              Tiruveedhula, V V and Cook, James M and Chan, John D",
-  abstract = "The neglected tropical disease schistosomiasis infects over 200
-              million people worldwide and is treated with just one broad
-              spectrum antiparasitic drug (praziquantel). Alternative drugs are
-              needed in the event of emerging praziquantel resistance or
-              treatment failure. One promising lead that has shown efficacy in
-              animal models and a human clinical trial is the benzodiazepine
-              meclonazepam, discovered by Roche in the 1970's. Meclonazepam was
-              not brought to market because of dose-limiting sedative side
-              effects. However, the human target of meclonazepam that causes
-              sedation (GABAARs) are not orthologous to the parasite targets
-              that cause worm death. Therefore, we were interested in whether
-              the structure of meclonazepam could be modified to produce
-              antiparasitic benzodiazepines that do not cause host sedation. We
-              synthesized 18 meclonazepam derivatives with modifications at
-              different positions on the benzodiazepine ring system and tested
-              them for in vitro antiparasitic activity. This identified five
-              compounds that progressed to in vivo screening in a murine model,
-              two of which cured parasite infections with comparable potency to
-              meclonazepam. When these two compounds were administered to mice
-              that were run on the rotarod test, both were less sedating than
-              meclonazepam. These findings demonstrate the proof of concept
-              that meclonazepam analogs can be designed with an improved
-              therapeutic index, and point to the C3 position of the
-              benzodiazepine ring system as a logical site for further
-              structure-activity exploration to further optimize this chemical
-              series. \#\#\# Competing Interest Statement The authors have
-              declared no competing interest.",
-  journal  = "bioRxiv",
-  pages    = "2024.01.26.577323",
-  month    =  jan,
-  year     =  2024,
-  keywords = "Zamanian Papers",
-  language = "en",
-  doi      = "10.1101/2024.01.26.577323",
-  pdf      = {Mian et al. 2024 - Development of non-sedating antischistosomal benzodiazepines.pdf},
-  preview  = {Mian et al. 2024 - Development of non-sedating antischistosomal benzodiazepines.jpeg}
-}
-
   % preview = {brownian-motion.gif},
 
 

_pages/about.md

@@ -30,6 +30,10 @@ We are a research lab in the department of [Pathobiological Sciences](https://ww
   <div class="col-sm-7" markdown="block" style="float:right; height: 230px; border-radius: 8px; border-style: solid; border-color: #b509ac; border-width: 1px; text-align: left; margin: 0; padding-left: 2%; padding-right: 2%; padding-bottom: 0%; padding-top: 0.5%; font-size: 90%; line-height: 1.3; overflow-x: scroll;">
   <u>Lab News and Updates</u>
 
+  <code>Sep 2024</code>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Natalia Betancourt joins the lab as a PhD student through the CBMS program.
+
+  <code>Jul 2024</code>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clair, Elena, and Katie presented talks and posters at the 2024 AAVP Meeting and took home presentation awards.
+
   <code>Aug 2023</code>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kendra has successfully defended her PhD and will be starting a postdoc at UC-Berkeley. Congrats Dr. Dahmer!
 
   <code>Jul 2023</code>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New <a href="https://pubmed.ncbi.nlm.nih.gov/37566913/">paper</a> on Mansonella diagnostics and epidemiology in the Colombian Amazon.<br>

_pages/contact.md

@@ -4,7 +4,7 @@ permalink: /contact/
 title: contact
 description: Materials for courses you taught. Replace this text with your description.
 nav: true
-nav_order: 5
+nav_order: 6
 ---
 
 #### Positions

_pages/services.md

@@ -0,0 +1,40 @@
+---
+layout: page
+title: services
+permalink: /services/
+description: 
+
+nav: true
+nav_order: 5
+display_categories: [work, funding]
+horizontal: false
+---
+
+#### Antiparasitic Screening Services
+
+<br>
+<div class="row">
+    <div class = "col-sm-1">
+    </div>
+    <div class = "col-sm-10">
+        <img class="img-fluid z-depth-1 rounded" src="../assets/img/service/Fee-for-Service.png" alt="fee-for-service">
+    </div>
+    <div class = "col-sm-1">
+    </div>
+</div>
+<br>
+
+<code>Antiparasitic screening </code> We offer a range of powerful high-content antiparasitic and anthelmintic screening assays using phenotyping pipelines and software developed in our laboratory. We currently offer in vitro screening assays for insect and soil-transmitted helminths of veterinary, agricultural, and human health relevance. We provide parallel multivariate screening of the model nematode *C. elegans*. Our screening platforms are scalable and provide multivariate readouts of drug action and kinetics. The deliverables for each assay will include an overview of QC data and processing of image data into informatives plots. All raw data will be retained for a year post delivery.
+
+<code>Antiparasitic target assays</code> We offer additional services to help identify antiparasitic targets and guide structure-activity relationship studies, including procurement or creation of transgenic *C. elegans* strains for comparative phenotypic screening, forward genetic screens to identify mutations that alter drug responses, production of tissues for drug target engagement assays, and other customized deliverables. 
+
+<code>Assay pricing</code> Contact us for assay menus and pricing. Pricing will depend on the method of parasite rearing or procurement, the format and nature of drugs or chemicals provided, or other custom modifications of core experimental protocols or analysis pipelines.
+
+In vitro assays:
+- Filarial parasites: Dog heartworm (mf, L3, and L4), Brugia (adult males and females) 
+- Gastrointestinal nematodes: *Haemonchus contortus* (larval assasys)
+- Model nematodes: *C. elegans*
+
+We expect to have pipelines for in vivo anthelmintic efficacy and in vitro ectoparasiticide testing within the next year.
+
+